Supplementary Materials

Supplementary Material for:

Therapeutic Potential of Spleen Tyrosine Kinase Inhibition for Treating High-Risk Precursor B Cell Acute Lymphoblastic Leukemia

Tatiana Perova, Ildiko Grandal, Lauryl M. J. Nutter, Eniko Papp, Irina R. Matei, Joseph Beyene, Paul E. Kowalski, Johann K. Hitzler, Mark D. Minden, Cynthia J. Guidos, Jayne S. Danska*

*Corresponding author. E-mail: jayne.danska{at}

Published 14 May 2014, Sci. Transl. Med. 6, 236ra62 (2014)
DOI: 10.1126/scitranslmed.3008661

This PDF file includes:

  • Fig. S1. p53−/−; Prkdcscid/scidmouse leukemias display a pre-BCR–independent pro-B to pre-B cell transition, related to Fig. 1.
  • Fig. S2. Phospho-flow analysis of SYK-dependent signaling in B-ALL, related to Fig. 2.
  • Fig. S3. Assessment of apoptosis in double-mutant B-ALL after treatment with SYK inhibitors, related to Fig. 1.
  • Fig. S4. Dose-response effects of SYK inhibitors on SYK-dependent signaling in cell lines, related to Fig. 2.
  • Fig. S5. Dose-response effects of fostamatinib and BAY61 on SYK-dependent signaling in B-ALL, related to Fig. 2.
  • Fig. S6. Relationship between immunophenotype and SYK activation in B-ALL, related to Fig. 2.
  • Fig. S7. IC50 values for fostamatinib and BAY61 effects on B-ALL proliferation, related to Fig. 3.
  • Fig. S8. Relationship between SYK phosphorylation and activity of SYK inhibitors in B-ALL, related to Fig. 3.
  • Fig. S9. Relationship between pSRC inhibition and activity of dasatinib in BALL, related to Fig. 4.
  • Fig. S10. Fostamatinib reduces B-ALL tumor burden after xenografting into NSG mice, related to Fig. 5.
  • Fig. S11. Tumor burden in NSG mice at the start of fostamatinib regimen 2, related to Fig. 6.
  • Fig. S12. Fostamatinib decreases the burden of well-engrafted B-ALL, related to Fig. 6.
  • Table S1. Clinical characteristics of B-ALL samples used in phospho-flow and in vitro proliferation assays (Figs. 1 to 4).
  • Table S2. Clinical characteristics of 13 B-ALL samples used in xenotransplant studies (Figs. 5 and 6).

[Download PDF]